Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Vinay Rajani of HDFC Sec suggests Oracle Financial Services, Sun Pharma shares to buy
Indian equity markets experienced a significant selloff on May 18, with Sensex and Nifty 50 dropping over 1%. The BSE Sensex fell over 1,000 points, erasing nearly ₹9 lakh crore in investor wealth amid weak global cues and a bearish trend across sectors.
Unique Picks: 6 stocks held by only one MF scheme in April, falling up to 40% in CY26
An analysis of mutual fund portfolios revealed 29 stocks held exclusively by single schemes, with most underperforming in CY26. However, Satin Creditcare Network, Rossell Techsys, and Amanta Healthcare bucked the trend, delivering strong returns. Brooks Laboratories and EFC (I) were among those experiencing significant declines.
Q4 Results LIVE Updates: Dr. Reddy's, Dixon report results today; Indian Hotels, Anant Raj react
Q4 Results LIVE Updates: Its an earnings-heavy day on the Dalal Street today. Nifty 50 stock Dr Reddy's Laboratories is scheduled to report its numbers today. Dixon Tech, Berger Paints, Nazara Tech, INOX India, Cohance Lifesciences, Gopal Snacks, Kalpataru, KPR Mill, Max Financial Services, MobiKwik, MTAR Tech, Novartis, Pfizer, Religare, Keystone Developers, Sagility, Tata Power, Torrent Power, Texmaco Rail, V-Guard Industries, are among the other important results to track today. Watch this space for all the LIVE earnings updates.
Gold loans power Small Finance Banks' growth as microfinance asset quality weakens
Small Finance Banks are shifting focus to secured loans like gold loans. This move aims to stabilize their financial health and earnings. The unsecured microfinance sector continues to face high bad loan ratios. This strategic pivot is happening as regulators encourage diversification. Some larger banks are also growing their microfinance business. This change is crucial for long-term stability and growth.
Nippon India Mutual Fund raises stake in this healthcare stock. Do you own? - Mint
Nippon India Mutual Fund raises stake in this healthcare stock. Do you own?Mint
Where to invest now: SBI MF prefers large caps, pharma, PSU banks
Ruchit Mehta, Head of Research at SBI Mutual Fund, prefers CDMO and hospital plays within pharma, citing stronger growth prospects over generics. He sees large caps as attractive on valuations, while midcaps require selectivity amid earnings risks. PSU banks may outperform in the near term due to stronger loan growth, but asset quality risks could emerge over the next 2–3 quarters if global disruptions persist.
Sensex dives 850 pts, Nifty slips below 24,200 amid oil shock and weak global cues
The equity benchmark indices Sensex and Nifty tumbled on Thursday, extending losses for a second straight session. Firm crude oil prices and ongoing geopolitical tensions rattled sentiment. Brent crude surged for the fourth consecutive day to around $103 per barrel amid uncertainty over US-Iran talks and fresh concerns around the Strait of Hormuz. Weak Asian cues and persistent foreign fund outflows deepened the sell-off. The Nifty slipped below the 24,200 mark, dragged by auto, PSU banks and consumer durables stocks, while pharma and healthcare shares saw selective buying. Investors stayed cautious, closely tracking the ongoing Q4 earnings season for further triggers.
Holding 10 or more mutual funds? You may be over-diversified — here’s the ideal number
While there is no magical number, most wealth advisors and financial planners that Mint talked to recommended that 4-6 funds spread across asset classes and stock categories can take care of the majority of the needs of an investor.
Stocks to Buy: Citi projects 20% upside for a stock that Mutual Funds lapped up in March
Citi expects Anthem Bio's revenue to grow at a 19% CAGR over financial year 2026-2028 and its Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) to grow at a 22% CAGR during the same timeframe.
'Weak and lacklustre': Why Jefferies is disappointed with Wipro earnings as ADRs fall nearly 3%
Wipro’s March quarter results missed expectations, with weak revenue growth, declining profit, and soft guidance. Jefferies highlighted slowing deal momentum, weakness in BFSI and healthcare, and client-specific declines, raising concerns over near-term growth despite stable margins and a buyback announcement.
Nippon India Mutual Fund Increases Stake in Syngene International to 7.12% - scanx.trade
Nippon India Mutual Fund Increases Stake in Syngene International to 7.12%scanx.trade
Wipro Q4 Preview: Profit may fall on margin pressures. Is buyback the only thing to cheer?
Wipro is expected to report steady revenue growth but weaker profitability in the March quarter, impacted by wage hikes, acquisition-related costs and subdued discretionary spending. Sequential growth remains muted despite acquisition support, while BFSI shows resilience, and healthcare remains weak. Investors will closely track margins, deal pipeline and AI outlook.